Symbols

SLNO

Soleno Therapeutics·NASDAQ

--(--)

SLNO fundamentals

SLNO Q4 2025 Earnings

Soleno Therapeutics (SLNO) released its earnings on Feb 25, 2026: revenue was 91.73M (YoY --), beat estimates; EPS was 0.8 (YoY +162.99%), beat estimates.

Revenue / YoY

91.73M

EPS / YoY

0.8

+162.99%

Report date

Feb 25, 2026

SLNO Earnings Call Summary for Q4,2025

Revenue & Profitability: Q4 2025 revenue $91.7M, full year $190.4M; net income $20.9M for 2025.
Market Penetration: 1,250 patient starts (12.5% of U.S. market), 859 active patients.
New Indications: Glycogen storage disease type 1 IND filing, targeting 2026 trial.
EU Progress: MAA submission for PWS, mid-2026 approval expected.
Financial Strength: $506M cash, transitioning to at-cost inventory.

Earnings

EPS

Revenue

Revenue & Expenses

SLNO has released its 2025 Q4 earnings report, with revenue of 91.73M, reflecting a YoY change of NaN%, and net profit of 43.36M, showing a YoY change of 177.45%. The Sankey diagram below clearly presents SLNO's revenue sources and cost distribution.

Key Indicators

Soleno Therapeutics (SLNO) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Soleno Therapeutics (SLNO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Soleno Therapeutics (SLNO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Soleno Therapeutics (SLNO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown